Paradromics Joins Neurotech Race With FDA Nod To Test BCI For Restoring Speech

 
• By Marion Webb
  
Paradromics received an FDA IDE to evaluate its Connexus BCI for speech restoration in a first clinical study, planned for the first quarter of 2026. (Paradromics)

More from Neurology

More from Device Area